Terns Pharmaceuticals Inc (TERN)
5.435
+0.14
(+2.55%)
USD |
NASDAQ |
May 03, 16:00
5.435
0.00 (0.00%)
After-Hours: 18:55
Terns Pharmaceuticals Research and Development Expense (Quarterly): 17.46M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 17.46M |
| September 30, 2023 | 14.83M |
| June 30, 2023 | 14.15M |
| March 31, 2023 | 17.06M |
| December 31, 2022 | 10.66M |
| September 30, 2022 | 12.16M |
| June 30, 2022 | 8.662M |
| March 31, 2022 | 8.136M |
| December 31, 2021 | 9.462M |
| Date | Value |
|---|---|
| September 30, 2021 | 7.153M |
| June 30, 2021 | 5.961M |
| March 31, 2021 | 8.735M |
| December 31, 2020 | 7.77M |
| September 30, 2020 | 5.404M |
| June 30, 2020 | 7.611M |
| March 31, 2020 | 7.244M |
| December 31, 2019 | 7.556M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
5.404M
Minimum
Sep 2020
17.46M
Maximum
Dec 2023
10.00M
Average
8.662M
Median
Jun 2022
Research and Development Expense (Quarterly) Benchmarks
| Viking Therapeutics Inc | 24.10M |
| Eli Lilly and Co | 2.523B |
| Pfizer Inc | 2.493B |
| Amgen Inc | 1.534B |
| Madrigal Pharmaceuticals Inc | 70.64M |